BioCentury
ARTICLE | Clinical News

TPI 287: Interim Phase I/II data

November 17, 2014 8:00 AM UTC

Interim data from 13 evaluable patients with recurrent GBM who progressed following prior treatment with radiation and temozolomide in the open-label, dose-escalation, U.S. Phase I/II CB-017 trial sho...